Advertisement
Mr. Han has over 20 years of medical sales experiences. Prior to joiningLiang Fang, Mr. Han was General Manager of the OTC Division of Tianjin TaipingPharmaceutical Company for two years. Prior to such time, he servedapproximately seven years as Vice General Manager and Chief of MarketingOfficer of Beijing Yongkang Pharmaceutical Company. Mr. Han has a bachelordegree of business management from Air Force Institute of Logistics.
Advertisement
"Mr. Han has strong management skills in medical sales and marketing andlogistics, proven with his previous tenure in both state-owned enterprises andprivate entities," said Dr. Zhong Yi Liu, Chairman and Chief Executive Officerof the Company. "We are bringing a strong leader to our OTC Division tofurther grow the OTC Division and lead a team of approximately 40 employees,of which approximately half of such employees are medical sales professionals.We are confident that Mr. Han's expertise in the area will assist theexpansion of our OTC business into 2012, as well as efficiency in delivery ofservices to drug stores in Beijing."
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer ofprescription drugs and a licensed national seller of pharmaceutical items inthe People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd.and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug developmentpipeline is focused on the treatment of cerebro-cardiovascular disease, asthma,and diabetes. More than 8,000 products are sold by Liang Fang directly andindirectly through its national sales channels to hospitals, clinics and drugsstores in 30 provinces.
Safe Harbor Statement
This press release contains "forward-looking statements" within themeaning of the "safe-harbor" provisions of the Private Securities LitigationReform Act of 1995. Forward-looking statements include, without limitation,any statement that may predict, forecast, indicate, or imply future results,performance or achievements, and may contain the words "estimate," "project,""intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,""will likely," "should," "could," "would," "may," or words or expressions ofsimilar meaning. Such statements are not guarantees of future performance andcould cause the actual results of the Company to differ materially from theresults expressed or implied by such statements, including, but not limited to,changes from anticipated levels of sales, future national or regional economicand competitive and regulatory conditions, changes in relationships withcustomers, access to capital, increased costs, difficulties in developing andmarketing new products, marketing existing products, customer acceptance ofexisting and new products, the time to get new drugs approved by the StateFood and Drug Administration and other factors. Additional informationregarding risks can be found in the Company's Annual Report on Form 10K andits older filings with the SEC. Accordingly, although the Company believesthat the expectations reflected in such forward-looking statements arereasonable, there can be no assurance that such expectations will prove to becorrect. The Company has no obligation to update the forward-lookinginformation contained in this press release.For more information, please contact: Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Tel: +86-10-6389-9868 Email: [email protected]
SOURCE Lotus Pharmaceuticals, Inc.
